Advertisement mid banner S-Tech 1
ARM Innovation Hub
Advertisement: Mogrify mid banner
Mid banner advertisement: BDO
Advertisement: Excalibur Healthcare mid banner
Advertisement: RSM mid banner
Advertisement: CJBS mid banner
Advertisement: Simpsons Creative
Advertisement: Kao Data Centre mid banner
Advertisement: EBCam mid banner
Advertisement: Cambridge Network mid banner
Advertisement: HCR Hewitsons mid banner
Advertisement: partnersand mid banner
Barr Ellison Solicitors – commercial property
14 July, 2021 - 23:26 By Tony Quested

Sosei and US partner to drive drug discovery revolution

A new UK-US collaboration jointly anchored from Cambridge and Connecticut is set to leverage AI and machine learning to transform drug discovery and development.

Sosei in Cambridge and InveniAI® are driving the initiative. Their objective is to identify new therapeutic product concepts for immune diseases where an AI and ML based approach can be applied to generate compelling evidence for the role of G-protein coupled receptors (GPCRs) in relevant immunomodulatory pathways.

The goal is to use these targets as a basis to generate novel compounds that could improve responses to existing immunotherapies.The collaboration will combine InveniAI’s AI-powered platform for target discovery with Sosei Heptares’ world-leading GPCR structure-based drug design and early development capabilities generate and advance transformative therapeutics across disease indications that remain with high unmet medical needs.

Dr Miles Congreve, chief scientific officer, Sosei Heptares, said: “We are excited to work together with InveniAI and look forward to integrating our unique capabilities to seek and identify new links between undrugged GPCR targets and compelling disease indications.

“This collaboration has the potential to further extend our GPCR-focused drug discovery and early development capabilities. GPCRs represent an important class of pharmaceutical targets, and it is estimated that about 30 per cent of known drugs have their mode of action through a relatively small number of GPCRs. 

“This leaves a significant number of remaining GPCR targets that could be attractive for therapeutic intervention. InveniAI’s AlphaMeld® platform will deconvolute the biology of disease and industrialise target discovery by rapidly unravelling connections between GPCR targets and diseases with high unmet need.”

InveniAI’s chief business officer, Aman Kant, added: “We have consistently demonstrated our AI capabilities in generating clinic-ready programs across various therapeutic modalities, including biologics, small molecules, and nucleotide-based therapies.

“This collaboration will leverage InveniAI’s AI-based high-throughput discovery pipeline with Sosei Heptares’ complementary chemistry approach to deliver drug candidates efficiently, at a scale, and with an enhanced probability of clinical success. 

“We continue to be excited about AlphaMeld’s potential, as numerous candidates have now progressed to various stages in clinical development as far as NDA submission.”

Newsletter Subscription

Stay informed of the latest news and features